Bispecific antibodies (BsAbs) have demonstrated efficacy in newly diagnosed and
relapsed/refractory (R/R) lymphomas. BsAbs form immune synapses between effector cells …

T cell engagers (TCE) such as chimeric antigen receptor (CAR) T cell therapy and bispecific
antibodies (BiAbs) for the treatment of multiple myeloma (MM) have significantly improved …

Background Patients with relapsed/refractory multiple myeloma are at increased risk of
infection. Infections during treatment with teclistamab, the first B‐cell maturation antigen …

Bispecific antibodies (bsAbs) are engineered molecules designed to target two different
epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets …

The objective of our study was to report real-world data on the safety and efficacy of
standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM) …

Bispecific antibodies [bsAb] targeting B-cell maturation antigen [BCMA] and G-protein-
coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and …

Introduction Multiple new drugs have been approved over the past 5 years for the treatment
of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely …

Abstract Purpose of Review The introduction of bispecific antibodies is one of the most
significant recent advances in the treatment of relapsed/refractory multiple myeloma. This …

The authors raised salient points about the importance of accounting for differences in the
duration of follow-up and drug exposure between trials to reduce variation in reporting and …

Introduction T-cell redirecting bispecific antibodies (BsAbs), targeting B-cell maturation
antigen (BCMA) or G-protein–coupled receptor class C group 5 member D (GPRC5D), are …